Citations

Clear

2960 citation(s) found for "Kim, P".

Abstract PD4-07: Association between age at diagnosis and survival among young BRCA carriers with breast cancer: results from an international multicenter hospital-based cohort study
Meacci, Arianna , Gil, M. Fragío, Klocker, E., Coussy, Florence , Kim, H., Molho, R. Bernstein, Meglio, A. Di, Pogoda, K., Bajpai, J. , Wildiers, Hans, Balmana, J., Moore, H. C., Phillips, K., Partridge, A. H., Rousset-Jablonski, C., PeccatorI, F. A., Toss, Angela, Renaud, T., Anghelone, Chiara Annunziata Pasqualina, Cruz, A. Benitez, Lee, J. E., Fruscio, R, Cui, W., Wong, S. M., Lee, M., Rozenblit, M., Villarreal-Garza, C., Matikas, A., Dieci, M. V., Marchis, Laura De , Plichta, J. K., Ruddy, K. J., Guven, D. Can, Puglisi, F., Kemp, Zoë, Meireles, P. A., Delucchi, Virginia , Lambertini, M., Blondeaux, Eva , Gil, Mónica Fragío , Molho, R. Bernstein, Hilbers, Florentine , Meglio, Antonio Di , Kwong, Ava , Pogoda, K. , Agostinetto, Elisa , Moore, Halle C F , Partridge, Ann H. , Rousset‐Jablonski, Christine , Peccatori, Fedro A , Toss, Angela , Renaud, Tiphaine , Paluch–Shimon, Shani , Rozenblit, M., Vernieri, Claudio , Villarreal‐Garza, Cynthia , Matikas, Alexios , Plichta, J. K., Ruddy, Kathryn J. , Puglisi, Fabio , Kemp, Z.E., Meireles, P., Mastro, Lucia Del , Lambertini, Matteo

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PD4-07-PD4-07

10.1158/1557-3265.sabcs25-pd4-07 Get It

Abstract Background Young age is a known risk factor for breast cancer recurrence and mortality, particularly in hormone receptor-positive disease. However, no specific evidence exists on whether age at diagnosis influences clinical behavior and outcomes among carriers of germline BRCA pathogenic or likely pathogenic variants (PVs). Methods The BRCA BCY Collaboration (NCT03673306) is an international, multicenter, hospital-based, retrospective cohort study including women with germline BRCA1 and/or BRCA2 PVs and diagnosed with stage I-III breast cancer at the age of 40 years or younger between January 2000 and December 2020. The present analysis aimed to evaluate clinical features and outcomes of breast cancer in young BRCA carriers according to age at diagnosis, by comparing patients aged ≤30 years with those aged 31-35 and 36-40 years at breast cancer diagnosis. The primary endpoint was disease-free survival (DFS). Overall survival (OS) was a secondary endpoint. Multivariable Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs), adjusting for risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) (time-dependent), and stratifying by country, year of diagnosis, tumor size, nodal involvement, tumor grade and hormone receptor status. Results From 109 centers in 5 continents, 5350 young BRCA carriers were included, of whom 1106 (20.7%) were ≤30 years of age, 1945 (36.4%) were 31-35 years and 2299 (43.0%) were 36-40 years at the time of breast cancer diagnosis. Compared to patients aged 31-35 and 36-40 years, those aged ≤30 years were more likely to harbor BRCA1 PVs (71.3%, 62.4%, 61.1%, respectively), to present with high-grade (G3 in 71.3%, 66.6%, 65.0%, respectively), triple-negative breast cancer (56.3%, 48.1%, 46.6%, respectively), and less frequently smaller tumor size (T1: 31.7%, 36.6% and 39.5%, respectively). Consequently, chemotherapy was administered more frequently among patients aged ≤30 years (94.4%, 92.6%, 89.7%, respectively). At a median follow-up of 8.2 years (IQR, 4.7-12.8), 8-year DFS rate was 65.0% among patients aged ≤30 years, 64.7% in the 31-35 years group, and 65.8% in the 36-40 years group. No significant association between age at diagnosis and DFS outcome was observed (31-35 vs. ≤30 years: aHR 1.03, 95% CI 0.89-1.19; 36-40 vs. ≤30 years aHR 1.00, 95% CI 0.87-1.16). Similarly, no significant association between age at diagnosis and OS was observed (31-35 vs. ≤30 years: aHR 1.10, 95% CI 0.86-1.41; 36-40 vs. ≤30 years: aHR 1.11, 95% CI 0.87-1.43). Subgroup analyses by specific BRCA gene, tumor subtype, tumor size, nodal status, and chemotherapy use revealed no statistically significant interaction with age at diagnosis in terms of DFS or OS (all p for interaction > 0.05). Specifically, no significant differences between age groups were observed among patients with luminal-like tumors for both DFS and OS. Conclusions In this unique international cohort of BRCA carriers diagnosed with breast cancer at a young age (≤40 years), we found no significant differences in DFS nor OS across different age groups. Notably, very young age (≤30 years) at diagnosis was not associated with worse outcomes compared to 31-35 years or 36-40 years. Age per se should not be considered a negative prognostic factor in BRCA carriers when appropriate treatment is provided. Citation Format: E. Blondeaux, A. Meacci, M. Fragío Gil, E. Klocker, F. Coussy, H. Kim, R. Bernstein Molho, F. Hilbers, A. Di Meglio, A. Kwong, K. Pogoda, J. Bajpai, H. Wildiers, E. Agostinetto, J. Balmana, H. C. Moore, K. Phillips, A. H. Partridge, C. Rousset-Jablonski, F. A. Peccatori, A. Toss, T. Renaud, C. Anghelone, A. Benitez Cruz, S. Paluch-Shimon, J. Lee, R. Fruscio, W. Cui, S. M. Wong, M. Lee, M. Rozenblit, C. Vernieri, C. Villarreal-Garza, A. Matikas, M. Dieci, L. De Marchis, J. K. Plichta, K. J. Ruddy, D. Can Guven, F. Puglisi, Z. Kemp, P. A. Meireles, L. Del Mastro, V. Delucchi, M. Lambertini. Association between age at diagnosis and survival among young BRCA carriers with breast cancer: results from an international multicenter hospital-based cohort study [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD4-07.
Abstract PD12-01: Surgical management of young BRCA1/2 carriers with early onset breast cancer
Wong, S. M., Delucchi, Virginia , Coussy, F., Molho, R. Bernstein, Linn, S., Meglio, A. Di, Kwong, A., Pogoda, K., Nevelsteen, Ines , Balmana, J., Moore, H. C., Toss, Angela, Ferrari, A., Rousset-Jablonski, C., Renaud, T., Phillips, K., PeccatorI, F. A., Ipina, M. Agustina, Ryu, J. M., Kui, W., Lee, M., Fruscio, R, Rozenblit, M., Vernieri, C., Matikas, A., Dieci, M. V., Couch, F. J., Marchis, Laura De , Hwang, S. E., Mendez, D. Aguilar-y, Guven, D. Can, Swain, Monique , Gianni, Claudia, Montagna, G., Lambertini, M., Kim, H., Wong, S. M., Blondeaux, Eva , Coussy, Florence , Molho, R. Bernstein, Linn, Sabine C. , Meglio, Antonio Di , Kwong, Ava , Pogoda, K. , Agostinetto, Elisa , Moore, Halle C F , Toss, Angela , Rousset‐Jablonski, Christine , Renaud, Tiphaine , Peccatori, Fedro A , Paluch–Shimon, Shani , Rozenblit, M., Vernieri, C., Matikas, Alexios , Couch, F.J., Mendez, D Aguilar Y, Guven, D. Can, Gianni, C., Spinaci, Stefano , Montagna, Giacomo , Lambertini, M.

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PD12-01-PD12-01

10.1158/1557-3265.sabcs25-pd12-01 Get It

Abstract Background: Young BRCA carriers may undergo breast conserving surgery (BCS) or mastectomy with or without contralateral risk reducing mastectomy at the time of an index breast cancer diagnosis. A variety of factors may influence surgical decision making. Methods: The BRCA BCY Collaboration (NCT03673306) is an international, hospital-based, retrospective cohort study conducted at 109 centres across 5 continents including women with germline pathogenic or likely pathogenic variants (PV) in BRCA1/2 diagnosed between 2000 and 2020 with invasive stage I-III breast cancer prior to or at age 40 years. The primary objective of the present analysis was to evaluate surgical management in these patients. Breast surgery was defined as BCS, unilateral mastectomy, or bilateral mastectomy administered as part of primary treatment for a first diagnosis of invasive breast cancer. Multivariable logistic regression was used to determine factors associated with receipt of bilateral mastectomy. Results: Of 5660 eligible BRCA1/2 carriers, 4715 had unilateral stage I-III breast cancer with surgical treatment details available. The median age of the cohort was 35 years (IQR, 31-38 years). Overall, 1805 (38.3%) patients underwent BCS, 1752 (37.2%) underwent unilateral mastectomy, and 1158 (24.6%) underwent bilateral mastectomy. The proportion of young BRCA1/2 carriers undergoing BCS decreased over the study period (55.7% in 2000 vs. 27.0% in 2020), whereas the use of bilateral mastectomy significantly increased (8.0% in 2000 vs. 44.4% in 2020). Bilateral mastectomy was more common in women who had genetic testing performed before (57.0%) or within 6 months of a breast cancer diagnosis (38.5%), compared to those tested after diagnosis (5.1%, p<0.001). On multivariable analysis, compared to those tested after diagnosis, earlier genetic testing remained the strongest predictor of bilateral mastectomy receipt (testing prior to diagnosis: OR 20.7 [95% CI 15.3-28.1]; testing at diagnosis: OR 6.8 [95% CI 5.4-8.7]). Other predictors of bilateral mastectomy receipt included geographic region, later year of diagnosis, smaller tumor size, node negative disease, and neoadjuvant treatment. In subgroup analysis including 2327 patients who had genetic testing performed before or within 6 months of diagnosis, 42.0% underwent bilateral mastectomy, with the lowest rates reported in Asia/Africa (26.1%) and the highest rates reported in North America (66.4%, p<0.001). In adjusted subgroup analyses, BRCA1 PV, later year of diagnosis, smaller tumor size, node negative disease, neoadjuvant treatment, and geographic region remained independently associated with bilateral mastectomy. Conclusions: In this large, international study of young affected BRCA carriers, geographic region and timing of genetic testing strongly impacted surgical management. These data support early genetic testing for young women with breast cancer to help optimize local therapy decisions. Citation Format: S. M. Wong, E. Blondeaux, V. Delucchi, F. Coussy, R. Bernstein Molho, S. Linn, A. Di Meglio, A. Kwong, K. Pogoda, E. Agostinetto, I. Nevelsteen, J. Balmana, H. C. Moore, A. Toss, A. Ferrari, C. Rousset-Jablonski, T. Renaud, K. Phillips, F. A. PeccatorI, M. Agustina Ipina, S. Paluch-Shimon, J. Ryu, W. Kui, M. Lee, R. Fruscio, M. Rozenblit, C. Vernieri, A. Matikas, M. Dieci, F. J. Couch, L. De Marchis, S. E. Hwang, D. Aguilar-y Mendez, D. Can Guven, M. Swain, C. Gianni, S. Spinaci, G. Montagna, M. Lambertini, H. Kim. Surgical management of young BRCA1/2 carriers with early onset breast cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD12-01.
Abstract GS3-01: Menopausal Hormone Therapy and the Risk of Breast Cancer in Women with a Pathogenic Variant in BRCA1 or BRCA2
Kotsopoulos, J., Seca, M., Jacek, G., Huzarski, T., Møller, P., Kim, R. H., Singer, C. F., Karlan, B., Cajal, T. Ramon y, Pal, Tuya, Bordeleau, Louise , Foulkes, W., Tung, N. M., Couch, F. J., Neuhausen, S., Zakalik, Dana , Cybulski, C., Olopade, O. I., Metcalfe, K., Fruscio, R, Sun, P., Lubinski, J., Narod, S., Eisen, Andrea , Metcalfe, Kelly , Kim, Raymond H. , Metcalfe, Kelly A , Eisen, Andrea , Bordeleau, Louise , Kim, Raymond H , Kotsopoulos, Joanne , Seca, Marta , Huzarski, T., Møller, Pål , Kim, R.H., Singer, Christian F. , Karlan, Beth Y. , Aeilts, Amber M. , Pal, Tuya , Eisen, Andrew , Foulkes, William D. , Couch, F.J., Neuhausen, Susan L. , Cybulski, Cezary , Lubiński, Jan

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: GS3-01-GS3-01

10.1158/1557-3265.sabcs25-gs3-01 Get It

Abstract Background: Women with a pathogenic variant in the BRCA1 or BRCA2 gene (carriers) are at a high risk of developing ovarian cancer and recommended to undergo bilateral salpingo-oophorectomy at an early age resulting in surgical menopause. Menopausal hormone therapy (MHT) is the most effective way to mitigate the adverse outcomes of early menopause; however, the safety of MHT on breast cancer risk in this population has not been established. Methods: We conducted a prospective matched analysis of MHT use following menopause (predominantly surgical) and breast cancer risk in BRCA carriers using a matched prospective analysis to emulate a randomized clinical trial. Women without a history of any cancer or bilateral mastectomy and who were enrolled in a longitudinal study with detailed data collection were eligible for inclusion. Women who initiated MHT (exposed) after menopause were matched one-to-one to women who had not initiated MHT (unexposed) by gene, year of birth, and age at menopause, resulting in 676 matched pairs. Cox proportional hazards regression to estimate the hazard ratios (HR) and 95%CIs (CI) of incident breast cancer associated with MHT use. Results: After a mean follow-up of 5.6 years from the date of first MHT use in the exposed woman, there were 87 incident breast cancer cases in the exposed group (12·9%) and 128 cases in the unexposed group (18·9%) (P = 0·002). Compared to their unexposed match, women who used estrogen (E) experienced a significant decrease in the risk of breast cancer (HR = 0·37; 95%: CI 0·24-0·57). There was no protective (or adverse) effect associated with the use of E plus progestogen (E+P) (HR = 0·94; 95%CI 0·54-1·63), with progestogen alone (P) (HR = 1·14; 95%CI: 0·21-6·22) or with tibolone (HR = 0·57; 95%CI: 0·19-1·69). There were no diagnoses of breast cancer in the 43 women who used a CEE + bazedoxifene. Findings were similar for carriers of either gene mutation. Conclusion: To our knowledge, this represents the largest prospective report of MHT use and breast cancer risk in BRCA1 and BRCA2 carriers. Our findings showed no increase in the risk of breast cancer with the use of MHT, irrespective of gene mutation or formulation. These findings provide an evidence-based approach for the management of women at high-risk of breast cancer who are facing the acute and chronic effects of early surgical menopause. The safe use of MHT by BRCA carriers will continue to be an important research topic as formulations continue to evolve. Citation Format: J. Kotsopoulos, M. Seca, G. Jacek, T. Huzarski, P. Møller, R. H. Kim, C. Singer, B. Karlan, A. Aeilts, T. Ramon y Cajal, T. Pal, A. Eisen, L. Bordeleau, W. Foulkes, N. Tung, F. Couch, S. Neuhausen, D. Zakalik, C. Cybulski, O. Olopade, K. Metcalfe, R. Fruscio, P. Sun, J. Lubinski, S. Narod, Hereditary Breast Cancer Clinical Study Group. Menopausal Hormone Therapy and the Risk of Breast Cancer in Women with a Pathogenic Variant in BRCA1 or BRCA2 [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr GS3-01.
Clinical Presentation, Management, and Outcomes of Mycobacterium Bovis Bacillus Calmette-Guérin (BCG) Infections: A Single-center Retrospective Review
Kim, Myeongji , Saleh, Omar M Abu, Almeida, Natalia E. Castillo , Wengenack, Nancy L. , Deml, Sharon M., Comba, Işın Y. , Abu Saleh, Omar , Castillo, Natalia E , Comba, Isin Y , Saleh, Omar Abu

Mayo Clinic

Open Forum Infectious Diseases | February 14, 2026 | Volume: 13 | Issue: 3 | Pages: No page available

10.1093/ofid/ofag071 | PMID 41799262 Get It

Abstract Background Intravesical Mycobacterium bovis bacillus Calmette-Guérin (BCG) is standard therapy for high-risk nonmuscle-invasive bladder cancer. However, M bovis infections can occur and are not well understood. We aimed to characterize clinical phenotypes, diagnosis, management, and outcomes of culture-confirmed M bovis BCG infections following intravesical therapy for urothelial carcinoma. Methods A retrospective single-center review of adults with culture-confirmed M bovis infection after intravesical BCG (May 2009–July 2024) was conducted, abstracting clinical, microbiologic, treatment, and outcome data. Results Twenty-two White male patients (median age, 77 years) were included; 8 (36.4%) had localized genitourinary infection, 6 (27.3%) had dissemination limited to blood, and 8 (36.4%) had dissemination to other organs. Patients with bloodstream-only infection presented acutely (median 1.5 days after last BCG), whereas those with localized or organ-disseminated disease presented months to years after BCG, with the longest diagnostic delays in organ-disseminated infection. Despite all cases had culture-proven M bovis BCG infection, acid-fast smear, Mycobacterium tuberculosis complex polymerase chain reaction, and histopathology had limited sensitivity. All isolates were susceptible to rifampin, isoniazid, and ethambutol; all were resistant to pyrazinamide. Median treatment duration exceeded 9 months, 94.7% achieved cure, and attributable mortality was 5.0% (1 vascular graft infection). Conclusions M bovis BCG infections following intravesical therapy have favorable outcomes but are often associated with diagnostic delays and prolonged treatment. Early suspicion, comprehensive diagnostic evaluation, and timely surgical source control when indicated are critical. Management strategies should be tailored based on the extent of disease dissemination and individual host factors.
PPAR-Delta Agonist Therapies Did Not Rescue Hallmark Disease Phenotypes in Two Sets of Preclinical Trials in ALS TDP-43 and C9orf72 Model Mice
Luong, David T. , Niu, Chenchen, Tanji, Nolan, Duong, Ivy, Galero, Brandon, Zhang, Yong-Jie, Bennett, Craig L. , Spada, Albert R. La, Zhang, Yong‐Jie , Tanji, Nolan , Duong, Ivy , Galero, Brandon , Zhang, Yong-Jie , Bennett, Craig L , Niu, Chenchen , Kim, Eunice , Spada, Albert R. La

Mayo Clinic

International Journal of Molecular Sciences | February 13, 2026 | Volume: 27 | Issue: 4 | Pages: 1820

10.3390/ijms27041820 | PMID 41751955 Get It

Peroxisome-proliferator–activated receptor delta (PPARδ) regulates metabolic, mitochondrial, and inflammatory pathways implicated in neurodegeneration, making it an attractive therapeutic target for amyotrophic lateral sclerosis (ALS). In this study, we evaluated two PPARδ agonists, KD3010 and T3D-959, in two established ALS/FTD mouse models: an AAV-mediated C9orf72 G4C2-repeat expansion model (C9-149R) and the TDP-43Q331K transgenic model. Drug treatment was initiated prior to the emergence of key disease features and continued for 9–10 months. Comprehensive behavioral, neuropathological, and biomarker analyses revealed marked differences between the two models. C9-149R mice exhibited reduced body weight and subtle behavioral alterations without robust motor deficits, whereas TDP-43Q331K mice developed pronounced, progressive motor and cognitive impairments accompanied by a ~7-fold elevation in plasma neurofilament light chain (NfL). Despite effective target engagement—particularly for T3D-959—neither PPARδ agonist improved motor performance, cognitive behavior, neuroanatomical measures, plasma NfL levels, or disease-associated molecular phenotypes in either model. Prolonged KD3010 treatment resulted in loss of target engagement, consistent with drug tolerance, while T3D-959 sustained PPARδ activation without therapeutic benefit. Together, these findings demonstrate that PPARδ agonism is insufficient to modify disease progression in these ALS/FTD mouse models and underscore the importance of publishing well-powered negative preclinical studies to refine therapeutic strategies for ALS.
Factors Affecting Outcomes of Hindfoot Fusion Nails for Acute Injury: A Multicenter Study
Kim, Eugene , Tornetta, Paul , Carlson, Jon, Schultz, Alex, Wireman, Garrett , Ollivere, Benjamin J., Zheng, Amy , Patch, David , White, Tim D. , Heinz, Nicholas , Lahurd, Caroline Elizabeth, Ostrum, Robert F. , Baumann, Charles, Kottmeier, Stephen, Doany, Michael E. , Krause, Peter, Redlich, Nathan, Egol, Kenneth, Konda, Sanjit, Mir, Hassan, McCaskey, Meghan , Azer, Emil, Kusler, Jace E. , Beltran, Michael T., Mehta, Samir, Masada, Kendall M. , Hidden, Krystin A., Kuttner, Nicolas P. , Tornetta, Paul , Beltran, Michael J. , Kuttner, Nicolas, Schultz, Alexander , Ollivere, Ben J. , Zheng, Amy, Spitler, Clay A. , White, Tim, Stinner, Daniel J. , Baumann, Charles A. , Krause, Peter C. , Egol, Kenneth A. , Konda, Sanjit R. , Beltran, Michael, Mehta, Samir D. , Hidden, Krystin A.

Mayo Clinic

Journal of Orthopaedic Trauma | February 13, 2026 | Volume: 40 | Issue: 3 | Pages: 148-154

10.1097/bot.0000000000003104 | PMID 41685944 Get It

OBJECTIVE: To evaluate the effect of joint preparation and patient factors on outcomes and complications in patients treated acutely with hindfoot fusion nails for ankle and pilon fractures. METHODS: Design: Retrospective chart review. Setting: Thirteen US trauma centers and 2 UK trauma centers. Patient Selection Criteria: Ankle and pilon fractures (AO-OTA types A-C) from 2010 to 2020 acutely treated definitively with hindfoot fusion nail were reviewed. Patients at least 18 years old and with minimum 6 months follow-up or earlier diagnosis of complication were included. Exclusion criteria included nonambulatory at baseline, prior internal fixation that failed and underwent revision, and prior tibiotalar or subtalar arthrodesis. Outcome Measurements and Comparisons: The primary outcome was final postoperative ambulatory status. Secondary outcomes were infectious and fracture-related complications. RESULTS: One hundred forty-nine patients (75 men; 74 women; age 20–99; median 63 years) were treated for ankle (104) or pilon (45; 8A, 13B, 24C) fractures. Eighty-five patients (44%) had open fractures and 55 (37%) had diabetes. Thirty-six patients (24%) had joint preparation at the time of surgery. Forty-five (30%) were made weight bearing as tolerated postoperatively; the median time to mobilize was 1.5 days (0–210) and to full weight bearing was 35 days (0–1462). Fifty-seven patients (85%) returned to their preinjury ambulatory status, which was not affected by joint preparation (50% vs. 59%, P = 0.327). Joint preparation led to higher articular fusion rates (94% vs. 24%; P = 0.001) and fewer hardware removals (19% vs. 42%, P = 0.013), but trended toward a higher fracture nonunion rate (19% vs. 8%, P = 0.053). Forty-five patients (30%) had infectious complications, 60 (40%) had a fracture-related complication, and 67 (45%) had additional procedures. Open fractures did not lead to any differences in superficial or deep infection. Insulin-dependent diabetes was associated with higher rates of infectious complications (31% vs. 15%, P = 0.028) and amputation (17% vs. 4%, P = 0.029). CONCLUSIONS: Hindfoot fusion nails for acute ankle and pilon injuries had high complication rates. More complications occurred in patients with insulin-dependent diabetes. While 95% regained ambulation, only 57% returned to preoperative status. Joint preparation led to higher rates of articular fusion (94% vs. 24%, P < 0.001) but not fracture union (81% vs. 66%, P = 0.106). LEVEL OF EVIDENCE: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
Artificial Intelligence-Enabled Electrocardiography in Practice: A State-of-the-Art Review
Lee, Hak Seung , Croon, Philip, Lee, M, Poterucha, Timothy J. , Lin, Chin H., Son, J, Jeon, Ki Hyun , Tarabanis, Constantine , Lee, Seung‐Pyo , Kim, Kyung-Hee , Pandey, Ambarish , Kwon, J, Kim, Kyung‐Hee , Croon, Philip M , Lee, Min Sung , Poterucha, Timothy Joseph , Lin, Chin , Son, Jeong Min , Kwon, Joon-Myoung , Pandey, Ambarish

Mayo Clinic

Korean Circulation Journal | February 10, 2026 | Volume: 56 | Issue: 3 | Pages: 199

10.4070/kcj.2025.0486 | PMID 41866890 Get It

Evaluating Vulnerable Elders Survey-13 and FIL Geriatric Assessment in Older Adults With Aggressive Lymphomas
Johnson, P. Connor, Newcomb, Richard A., Nipp, Ryan D., Horick, Nora , Stacey, Julia, Yang, Daniel, Coffey, Bridget , Markovitz, Netana, Kaslow-Zieve, Emilia , Venkatachalam, Shruthi , El-Jawahri, Areej, Odejide, Oreofe O. , Johnson, Patrick Connor , Newcomb, Richard Andrew , Nipp, Ryan David , Tsang, Mazie , Markovitz, Netana H. , Kim, Elane M. , El‐Jawahri, Areej

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 9, 2026 | Volume: 24 | Issue: 2 | Pages: No page available

10.6004/jnccn.2025.7100 | PMID 41671426 Get It

Background: Aggressive non-Hodgkin lymphoma (aNHL) commonly occurs in older adults. However, geriatric assessments (GAs), which are associated with both survival and treatment-related toxicity, are infrequently performed due to logistical constraints. In this study, we examined how the brief, self-reported Vulnerable Elders Survey-13 (VES-13) screening tool and a comprehensive GA relate to clinical outcomes in this population. Methods: We conducted a longitudinal study of 105 adults aged ≥65 years who were initiating upfront chemoimmunotherapy for aNHL at 2 academic medical centers and their community affiliates between September 2020 and January 2023. Baseline frailty was evaluated using the Fondazione Italiana Linfomi (FIL) GA, which classifies patients as fit, unfit, or frail. The VES-13 was assessed both continuously and by categorizing patients as vulnerable (score ≥3). Using logistic regression controlling for covariates, we examined the association of VES-13 with grade ≥3 nonhematologic toxicity (toxicity), unplanned hospitalization within 6 months of treatment initiation, decline in quality of life (QoL) 1 year after therapy initiation, and death within 1 year of treatment initiation. In addition, we calculated the sensitivity and specificity of both the VES-13 and the FIL GA in identifying patients at risk for these outcomes. Results: The median patient age was 73 years (range, 64–99 years), with 42% aged ≥75 years. GA classified 40% of patients as fit, 10% as unfit, and 51% as frail, while 46% of patients had a VES-13 score ≥3, indicating vulnerability. VES-13 score was significantly associated with toxicity (odds ratio [OR], 1.18; P =.026), unplanned hospitalization (OR, 1.16; P =.043), QoL decline at 1 year (OR, 1.22; P =.027), and death within 1 year (OR, 1.49; P =.010). Using the VES-13 to define vulnerability (score ≥3), sensitivity and specificity were 59% and 61% for predicting toxicity, and 100% and 59% for predicting death within 1 year, respectively. FIL GA frailty had a sensitivity of 63% and specificity of 56% for predicting toxicity, and 100% sensitivity and 54% specificity for predicting death within 1 year. Conclusions: We found that VES-13 score was associated with survival, toxicity, health care utilization, and QoL decline, demonstrating similar sensitivity and specificity to the FIL GA. These findings underscore the potential utility of VES-13 as a screening instrument to identify older patients with aNHL at risk for adverse clinical outcomes.
Indocyanine green assists with sentinel lymph node mapping in pediatric and adolescent patients: A Pediatric Surgical Oncology Research Collaborative prospective observational study
Schermerhorn, Sophia M. V. , Vore, Emily , Bondoc, Alexander J, Ayala, Samantha, Kastenberg, Zachary J. , Arkin, Cameron, Malek, Marcus M. , Campwala, Insiyah, Aldrink, Jennifer H. , Horvath, Kyle , Piché, Nelson , Osman, Yasmin, Brown, Erin G, Doyle, Kathleen, Abril, Paige, Roach, Jonathan P, Ziogas, Ioannis A. , Rhee, Daniel S. , Chidiac, Charbel, Debertin, Julia , Craig, Brian T. , Lee, W. N., Barkhordar, Aaron, Joshi, Devashish , Stellon, Michael , Davies, Dafydd A., Boehmer, Chloé , Dasgupta, Roshni, Kastenberg, Zachary J , Arkin, Cameron , Malek, Marcus M , Aldrink, Jennifer H , Horvath, Kyle Z , Polites, Stephanie F. , Lee, William G , Barkhordar, Aaron , Joshi, Devashish , Beckhorn, Catherine , Dasgupta, Roshni , Bondoc, Alexander , Lautz, Timothy B. , Campwala, Insiyah , Brown, Erin G. , Roach, Jonathan P. , Chidiac, Charbel , Lal, Dave R. , Kim, Eugene S. , Le, Hau D. , Tracy, Elisabeth T. , Beckhorn, Catherine B , Dasgupta, Roshni

Mayo Clinic

Cancer | February 7, 2026 | Volume: 132 | Issue: 4 | Pages: No page available

10.1002/cncr.70274 | PMID 41653066 Get It

ABSTRACT Background Sentinel lymph node (SLN) biopsy is a critical staging tool in skin and soft tissue cancers. Although technetium lymphoscintigraphy is the most common adjunct, indocyanine green (ICG) demonstrates a promising alternative in pediatric, adolescent, and young adult (AYA) skin and soft tissue cancers. Methods and Objectives Evaluate the safety and efficacy of ICG in SLN biopsy (SLNB) in diverse pediatric and AYA solid cancers in a multi‐institutional environment. This is a prospective, observational study conducted at 13 member institutions in the Pediatric Surgical Oncology Research Collaborative between 2019 and 2023. Eligible patients underwent SLNB for primary or recurrent solid skin and soft tissue tumors. Peritumoral ICG was administered intraoperatively. Outcomes included SLN detection rates, histopathology of excised specimens, and surgeon‐reported assessment of utility. Safety was assessed through adverse event reporting. Results Forty SLNB procedures yielded 84 specimens: 13 melanoma (32.5%), 12 squamous cell carcinoma (30%), 11 non‐rhabdomyosarcoma soft tissue sarcoma (27.5%), two rhabdomyosarcoma (5%), one Ewing sarcoma (2.5%), and one malignant peripheral nerve sheath tumor (2.5%). Histologic evaluation identified 81 lymph nodes, 75 benign (89.3%) and six malignant (7.1%); three specimens were adipose tissue (3.6%). Of 81 lymph nodes, 76% were ICG‐positive. ICG had a sensitivity of 79.5%, a specificity of 33%, and a positive predictive value of 96%. All malignant nodes were ICG‐avid. There were no adverse reactions to ICG at 30 days. Conclusions ICG is a safe and effective adjunct for SLNB in pediatric and AYA soft tissue and skin malignancies.
Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve
Thériault, Sébastien , Holdcraft, Jacob A., Sharipova, Dinara , Dębiec, Radosław , Peloso, Gina M., Al‐Kassou, Baravan , Swan, Elena Ashikhmina , Ballotta, Andrea, Björck, Hanna M. , Braund, Peter S. , Corriveau, François, Dagenais, François, Francke, Michael, Gorbatov, Svetlana, Guo, Dongchuan, Habchi, Karam M, Scouarnec, Solena Le , Lichtner, Peter , Nguyen, Thy B., Norris, R., Pibarot, P, Simonet, Floriane, Tm, Sundt, Tessler, Idit , Willer, Cristen J., Wittmann, Susanne, Yang, Bo, Berezovets, Igor, Doppler, S. , Dreßen, Martina, Knoll, Katharina, Puehler, T., Schunkert, H, Bissell, Malenka M. , Bolger, Aidan, Brion, M, Citro, Rodolfo, Deeb, G. Michael, Corte, Alessandro Della, Dina, C., Eriksson, Per, Evangelista, Arturo , Franco-Cereceda, Anders, Gilon, Dan, Hetherington, Simon, Huggins, G S, Krane, Markus , Tourneau, Thierry Le, Limongelli, Giuseppe, Mathieu, P., Messika-Zeitoun, David, Michelena, Hector I., Milewicz, Dianna, Murdock, David R. , Nickenig, G., Nistri, Stefano, Nöthen, M, Samani, Nilesh J. , Schott, J., Webb, Tom R., Abdelilah-Seyfried, Salim, Schumacher, Johannes, Trenkwalder, Teresa , Body, Simon C. , Dina, Christian , Brión, Marı́a , Peloso, Gina M. , Webb, Tom R. , Faucherre, Adèle , Debiec, Radoslaw M , Peloso, Gina M , Al-Kassou, Baravan , Aranki, Sary , Ashikhmina Swan, Elena , Björck, Hanna M , Boureau, Anne Sophie , Braund, Peter S , Folkersen, Lasse , Guo, Dongchuan , Heydarpour, Mahyar , Isselbacher, Eric M , Jopling, Chris , Laporte, Fabien , Le Scouarnec, Solena , Li, Zhonglin , Lichtner, Peter , Maj, Carlo , Manikpurage, Hasanga D , Nguyen, Thy B , Norris, Russell A , Pibarot, Phillippe , Sarubbi, Berardo , Simonet, Floriane , Sundt, Thoralf , Surakka, Ida , Tessler, Idit , Yang, Bo , Doppler, Stefanie A , Dreßen, Martina , Knoll, Katharina , Puehler, Thomas , Schunkert, Heribert , Bissell, Malenka M , Bossé, Yohan , Bossone, Eduardo , Brion, María , Citro, Rodolfo , de Vincentiis, Carlo , Deeb, G Michael , Della Corte, Alessandro , Dina, Christian , Durst, Ronen , Ensminger, Stephan , Eriksson, Per , Evangelista, Arturo , Franco-Cereceda, Anders , Gilon, Dan , Giusti, Betti , Hetherington, Simon L , Huggins, Gordon S , Le Tourneau, Thierry , Limongelli, Giuseppe , Mathieu, Patrick , Messika-Zeitoun, David , Michelena, Hector I , Milewicz, Dianna M , Muehlschlegel, Jochen D , Murdock, David R , Nickenig, Georg , Nistri, Stefano , Nöthen, Markus M , Prakash, Siddharth K , Samani, Nilesh J , Jacques Schott, Jean , Webb, Tom R , Zaffran, Stéphane , Eagle, Kim , Body, Simon C , Holdcraft, Jacob A., Bellino, Michele , Dagenais, François, Forte, Amalia , Frigiola, Alessandro , Guo, Dongchuan , Isselbacher, Eric M. , Nelson, Christopher P. , Ong, Chin Siang , Roychowdhury, Tanmoy , Surakka, Ida , Willer, Cristen J , Aviérinos, Jean-François , Bolger, Aidan P. , Bossé, Yohan , Bossone, Eduardo , Citro, Rodolfo , Deeb, G. Michael , Corte, Alessandro Della , Gilon, Dan, Huggins, Gordon S. , Tourneau, Thierry Le , Mathieu, Patrick , Messika–Zeitoun, David , Nistri, Stefano , Nöthen, Markus M. , Pluchinotta, Francesca Romana , Prakash, Siddharth K. , Schott, Jean‐Jacques , Zaffran, Stéphane , Abdelilah‐Seyfried, Salim , Eagle, Kim A. , Schumacher, Johannes

Mayo Clinic

Circulation | February 6, 2026 | Volume: 153 | Issue: 14 | Pages: 1060-1076

10.1161/circulationaha.125.074752 | PMID 41645906 Get It

BACKGROUND: Bicuspid aortic valve (BAV) is a frequent congenital heart defect with a high heritability. Despite this, only a limited number of genes have been associated with the disease, and the molecular mechanisms remain unexplained in most cases. This study aimed to further understand the genetic architecture of BAV. METHODS: A genome-wide association study meta-analysis including 9631 cases among 65 677 participants was performed. Genes were prioritized using transcriptomic analyses based on RNA sequencing in relevant tissues, including human fetal and adult aortic valves. The impact of the knockdown or knockout of 4 candidate genes on cardiac development was verified in zebrafish. A polygenic risk score was developed, its association with BAV was evaluated in an independent cohort, and its association with a wide range of phenotypes (n=976) was evaluated in UK Biobank (n=355 618 individuals). RESULTS: Thirty-six genomic loci were identified, including 32 that were not described previously. Among the prioritized genes, KANK2 and ERBB4 were identified as potentially causal through transcriptomic analyses, colocalization, and Mendelian randomization based on gene expression in human aortic valves (n=484), whereas PRDM6 and STRN were prioritized using similar analyses from aortic (n=326) and left ventricular tissues (n=326), respectively. Targeting 4 candidate genes ( WNT4 , LEF1 , STRN , and KANK2 ) in zebrafish led to disruption in cardiac development. A polygenic risk score was associated with an odds ratio of 2.07 (95% CI, 1.90–2.25; P =5.43×10 -62 ) per SD for BAV and significantly associated with thoracic aortic aneurysm and atrial fibrillation in UK Biobank. CONCLUSIONS: This study supports a significant polygenic contribution to BAV, where the combination of multiple common variants in genes involved in heart morphogenesis disrupts aortic valve development.